Iovance Biotherapeutics, Inc. $IOVA Shares Sold by Caliber Wealth Management LLC KS

Caliber Wealth Management LLC KS lowered its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 10.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,450 shares of the biotechnology company’s stock after selling 5,750 shares during the quarter. Caliber Wealth Management LLC KS’s holdings in Iovance Biotherapeutics were worth $87,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Accredited Investors Inc. acquired a new position in shares of Iovance Biotherapeutics during the 1st quarter valued at about $33,000. WealthTrust Axiom LLC acquired a new position in shares of Iovance Biotherapeutics during the 1st quarter valued at about $33,000. Flputnam Investment Management Co. acquired a new stake in Iovance Biotherapeutics during the 1st quarter worth approximately $37,000. Gould Asset Management LLC CA acquired a new stake in Iovance Biotherapeutics during the 1st quarter worth approximately $39,000. Finally, Meeder Advisory Services Inc. acquired a new stake in Iovance Biotherapeutics during the 1st quarter worth approximately $51,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on IOVA. Wells Fargo & Company dropped their target price on shares of Iovance Biotherapeutics from $18.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, August 8th. Chardan Capital dropped their target price on shares of Iovance Biotherapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Zacks Research raised shares of Iovance Biotherapeutics to a “hold” rating in a research report on Tuesday, August 12th. The Goldman Sachs Group downgraded shares of Iovance Biotherapeutics from a “neutral” rating to a “sell” rating in a research report on Tuesday, July 15th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Iovance Biotherapeutics in a research report on Tuesday, August 19th. Six analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $11.90.

Iovance Biotherapeutics Trading Down 5.3%

Shares of IOVA stock opened at $2.15 on Thursday. The company has a market capitalization of $777.98 million, a PE ratio of -1.75 and a beta of 0.83. The firm has a fifty day simple moving average of $2.28 and a 200-day simple moving average of $2.38. Iovance Biotherapeutics, Inc. has a twelve month low of $1.64 and a twelve month high of $12.51.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The firm had revenue of $59.95 million during the quarter, compared to analysts’ expectations of $67.14 million. Iovance Biotherapeutics had a negative net margin of 161.44% and a negative return on equity of 52.87%. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. Equities research analysts predict that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.